Please login to the form below

Not currently logged in
Email:
Password:

Prostvac

This page shows the latest Prostvac news and features for those working in and with pharma, biotech and healthcare.

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

CV301 is Bavarian Nordic’s lead cancer vaccine after its much-delayed Prostvac candidate for prostate cancer failed to meet the mark in a phase III trial last year, wreaking havoc ... The setback was also a big disappointment for Bristol-Myers Squibb

Latest news

  • BMS signs $975m deal for Bavarian Nordic cancer vaccine BMS signs $975m deal for Bavarian Nordic cancer vaccine

    Furthermore, Bavarian Nordic could also receive regulatory milestone payments of $110m, up to $495m in sales milestones as well as tiered double-digit royalties on future sales of Prostvac. ... Analysts at Edison Research have predicted that Prostvac

  • Developing therapeutic cancer vaccines Developing therapeutic cancer vaccines

    Viral-vector based vaccines are also in the works. BN ImmunoTherapeutics and the US NCI are developing a viral-vector based vaccine, rilimogene galvacirepvec-rilimogene glafolivec (PROSTVAC), which is in phase

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics